eosinophilic phenotype
2 drugsPredictive biomarker for patient selection in 12 indications
2
Approved Drugs
12
Indications
2
Companies
eosinophilic phenotype is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 12 indications including Asthma, Chronic Rhinosinusitis, Chronic Obstructive Pulmonary Disease. Explore the targeted therapies, indications, testing methods, and companies developing eosinophilic phenotype drugs below.
Search eosinophilic phenotype Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting eosinophilic phenotype
eosinophilic phenotype Indications
Asthma Chronic Rhinosinusitis Chronic Obstructive Pulmonary Disease Eosinophilic Granulomatosis with Polyangiitis Hypereosinophilic Syndrome Atopic Dermatitis Chronic Rhinosinusitis with Nasal Polyps Eosinophilic Esophagitis Prurigo Nodularis Chronic Spontaneous Urticaria Bullous Pemphigoid Allergic Fungal Rhinosinusitis